Alnylam Pharmaceuticals | ALNY - Pre Tax Profit

Stock Price
323.49
Daily Change
-3.81 -1.16%
Monthly
-1.42%
Yearly
30.37%
Q1 Forecast
322.73

Alnylam Pharmaceuticals reported $161.14M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 73.5M Dec/2024
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 5.17B 637M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 6.23B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Tectonic Therapeutic USD -19.04M 25K Sep/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xencor USD -4.27M 1.76M Dec/2025